: Malaria during pregnancy is a major health risk for both the Background mother and the foetus. Pregnancy has been shown to influence the pharmacokinetics of a number of different antimalarial drugs. This might lead to an under-exposure in these patients which could increase the risk of treatment failure and the development of drug resistance. The study aim was to evaluate the pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant patients using a population modelling approach.
was best described by a one-compartment disposition model with first-order elimination. Pregnant women had a 21% higher elimination clearance of dihydroartemisinin, compared to non-pregnant women, resulting in proportionally lower drug exposure. In addition, initial parasitaemia and liver enzyme levels (alanine aminotransferase) were found to affect the relative bioavailability of artesunate.
: Results presented here show a substantially lower drug Conclusions exposure to the antimalarial drug dihydroartemisinin during pregnancy after standard oral treatment of artesunate and mefloquine. This might result in an increased risk of treatment failure and drug resistance development, especially in low transmission settings where relative immunity is lower.
: 
Introduction
Malaria infection during pregnancy has been associated with major adverse health outcomes for both the mother and the foetus. In 2007, there were an estimated 85 million pregnancies in areas of endemic P. falciparum malaria 1 . Pregnant women are more likely to get bitten by the vector, and to develop severe malaria 2, 3 . Malaria during pregnancy has also adverse consequences for the foetus resulting in an increased risk of intrauterine growth retardation, low birth weight, stillbirth, and infant morbidity and mortality 4 . The World Health Organization (WHO) is today recommending artemisinin based combination therapy (ACT) as first line therapy of uncomplicated P. falciparum malaria. This recommendation includes pregnant women in their second and third trimester 5, 6 . ACTs include an artemisinin derivative (i.e. artesunate, artemether, dihydroartemisinin) together with a longer acting drug (i.e. mefloquine, piperaquine, lumefantrine, amodiaquine) 7 . The artemisinins are highly effective, resulting in rapid parasite clearance during the first days of treatment 8 . The longer acting partner drugs are responsible for eliminating residual parasites to prevent recrudescent malaria.
Artesunate is rapidly converted by pre-systemic hydrolysis, systemic esterases and cytochrome P450 (CYP) 2A6 into its active metabolite dihydroartemisinin 9, 10 . Dihydroartemisinin is metabolized into inactive metabolites by glucuronidation by UDP-glucuronosyltransferase (UGT) 1A9 and 2B7 11 .
Pregnancy-related changes in the exposure to artesunate and dihydroartemisinin have been studied previously [12] [13] [14] . Morris et al. found a pregnancy-related increase in dihydroartemisinin clearance after oral artesunate treatment, resulting in approximately 42% lower drug exposure. Kloprogge et al. studied both intravenous and oral doses of artesunate in pregnant and non-pregnant women. Intravenous administration of artesunate showed similar disposition pharmacokinetics in both pregnant and non-pregnant women. However, a 23% decreased bioavailability of artesunate was observed after oral dosing which was explained by an increased pre-systemic activity during pregnancy.
A few other antimalarial drugs (e.g. chloroquine, lumefantrine and dihydroartemisinin) have shown a lower drug exposure in pregnant women compared to non-pregnant women, resulting in an increased risk for treatment failure and resistance development [15] [16] [17] [18] [19] [20] [21] .
The main aim of the present study was to evaluate the population pharmacokinetics of artesunate and its active metabolite, dihydroartemisinin, in a comparative study in pregnant and non-pregnant patients with uncomplicated P. falciparum malaria in Burkina Faso.
Methods

Study design and ethical approval
The study was conducted at the Nanoro District Hospital, Nanoro 
Study subjects
Pregnant and non-pregnant women with uncomplicated P. falciparum malaria mono-infection (defined as <50 000 parasites/µL and with no danger signs of severe malaria) were identified in two health facilities, the Centre de Sante´ et de Promotion Sociale (CSPS) of Nazoanga and of Nanoro, Burkina Faso. Non-pregnant women were selected to match the recruited pregnant women by age (either less or more than 20 years old) provided that they were residing in the same village as the pregnant women. Inclusion criteria for the study were; gestational age of more than 12 weeks, P. falciparum infection with a parasite density of less than 50,000 parasites/µL, willingness to sign or thumb print the written consent form, willingness to stay in the hospital for three days and to return for regular follow-up visits until delivery for treatment and observation, willingness to deliver at the health facility. A woman was excluded from the study if; she had a history of drug sensitivity to the studied drug or recent treatment with antimalarials or drugs known to interact with the studied drug, presence of any danger signs, physical findings of severe illness/severe anaemia, inability to tolerate oral medicine, chronic medical conditions requiring special care which could not be met by the study. Study procedures and objectives were explained in the local language by the study physician before obtaining a signed informed consent.
Drug regimen and blood sampling
Treatment comprised a fixed-dose of artesunate/mefloquinecontaining tablets (100 mg of artesunate and 220 mg of mefloquine) provided by Farmaguinhos, Rio de Janeiro, Brazil. A target daily dose of 8 mg/kg/day of mefloquine and 3.6 mg/kg/day of artesunate were given for three days to each patient. Number of tablets received was planned according to standard dosing according to body weight; women weighing <50 kg, 50-60 kg and >60 kg received a daily dose of 1.5, 2 and 2.5 tablets, respectively. Treatment was supervised and given after food.
Blood samples (2 mL) for pharmacokinetic analysis of artesunate and dihydroartemisinin were obtained by venous puncture or via a three-way tap attached to a catheter. Samples were collected before treatment and during the first day of treatment at time points: 0.25, 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours after dose. All samples were placed on ice immediately after blood collection and processed within 15 minutes. Plasma samples were obtained after centrifugation at 1,500g for 10 minutes at 4°C and stored in liquid nitrogen until shipment on dry ice to the Department of Clinical Pharmacology, MORU, Bangkok, Thailand, for measurement of drug concentrations.
Amendments from Version 1
No major changes have been made with respect to analysis and/or results, since all review comments could be addressed adequately with text edits to clarify issues raised during the review process. The largest edit was the addition of a discussion on the appropriateness of using the transit compartment absorption model.
Any further responses from the reviewers can be found at the end of the article
REVISED
Drug analysis
Samples were extracted by solid phase extraction and quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method 23 . Briefly, artesunate and dihydroartemisinin standards and isotope-labelled internal standards were provided by the WorldWide Antimalarial Resistance Network (WWARN). Separation was performed using an Agilent 1200 system consisting of a binary LC pump, a vacuum degasser, a temperature-controlled micro wellplate autosampler set at 4°C and a column compartment set at 40°C (Agilent technologies, Santa Clara, USA). Quantification was performed using an API 5000 triple quadrupole mass spectrometer (Applied Biosystems/MDS SCIEX, Foster City, USA), with a TurboVTM ionization source (TIS) interface operated in the positive ion mode.
Data acquisition was performed using Analyst 1.5 (Applied Biosystems/MDS Sciex, Foster City, CA, USA). The lower limit of quantification (LLOQ) was 1.2 ng/mL and 2.0 ng/mL for artesunate and dihydroartemisinin, respectively. The total assay coefficient of variation was less than 7% for all quality control samples of artesunate (i.e. 2.90, 51.7 and 546 ng/mL, <3.5%) and dihydroartemisinin (i.e. 5.87, 117 and 1880 ng/mL, <6.4%) in this study. The laboratory participates in the WorldWide Antimalarial Resistance Network (WWARN) quality control and assurance proficiency testing program with satisfactory performance 24 . Pharmacokinetic results of mefloquine will be reported elsewhere.
Pharmacokinetic analysis
The population pharmacokinetic properties of artesunate and dihydroartemisinin were analysed using nonlinear mixed-effects modelling of the logarithmic plasma concentrations (NONMEM version 7. Artesunate and dihydroartemisinin were modelled simultaneously and complete conversion of artesunate into its metabolite, dihydroartemisinin, was assumed 9, 26 . The first-order conditional estimation (FOCE) method with interactions was used in the model building process. Data below the LLOQ was modelled as missing data (M1), categorical data (M3) or fixed to half of the LLOQ (M5) 27 . When censored data were implemented with the M3-method a Laplacian estimation method was used.
Objective function value (OFV; proportional to minus twice the log likelihood of the observed data) and goodness-of-fit were used for model discrimination and graphical analysis, respectively. A drop in OFV of 3.84 was considered a significant (p=0.05) improvement in model fit when comparing two hierarchical models (one degree of freedom difference). One-two-and three-compartment models with first-order elimination from the central compartment were fitted to the plasma concentrationtime data. Several different absorption models were evaluated (zero-order, first-order, absorption lag-time, sequential absorption, and a flexible transit compartment model with 1-10 fixed transit compartments). Inter-individual variability was evaluated exponentially on all parameters in the model (Eq. 1).
where θ i is the individual parameter for the i th patient and θ TV is the typical value for parameter θ. η i is the inter-individual variability for parameter θ, assumed to be normally distributed with mean zero and variance ω 2 . Relative bioavailability of artesunate was evaluated by fixing the population value to unity and estimating the inter-individual variability.
The residual random variability was modelled with two separate additive error models (i.e. artesunate and dihydroartemisinin) on the log-transformed drug concentrations, being essentially equivalent to an exponential residual error on an arithmetic scale.
Body weight was evaluated as an allometric function on all clearance and volume parameters. The allometrically scaled parameters were centered on the median body weight of the studied population and scaled to a power of 0.75 and 1 for clearance and volume parameters, respectively.
Stepwise forward inclusion (p<0.05) was used for all other continuous and categorical covariates followed by a stepwise backward exclusion (p<0.01). Parasite biomass, alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin levels, and haemoglobin levels at enrolment were tested as continuous covariates while pregnancy was evaluated as both a continuous (estimated gestational age; 0-8 months) and a categorical covariate (pregnant vs non-pregnant).
A categorical pregnancy effect was evaluated using a full covariate approach (i.e. the pregnancy effect was added simultaneously on relative oral bioavailability, all clearance parameters and on mean transit time). The full covariate model was bootstrapped (n=500) and the 80% confidence interval of the covariate effect on each of the pharmacokinetic parameters visualized to investigate the clinical impact and the predicted variability of the covariate effect.
Basic graphical goodness-of-fit was evaluated by plotting observed artesunate and dihydroartemisinin concentrations against individually and population predicted concentrations and by plotting conditionally weighted residuals against population predicted concentrations and time. Eta and epsilon shrinkages were also evaluated to assess reliability of goodness-of-fit characteristics 28 . Prediction-correct visual predictive checks were performed using 2,000 simulations. Bootstrap diagnostics stratified on pregnancy, were performed using 1,000 re-sampled datasets to obtain standard errors for parameter estimates and non-parametric confidence intervals to evaluate parameter precision.
The final model was also used to simulate pregnant (n = 1,000) and non-pregnant (n = 1,000) women in order to investigate the differences in secondary exposure parameters (AUC and C MAX ) associated with pregnancy. Simulated pregnant and non-pregnant women were identical with respect to body weight and other co-variates, except pregnancy. All individual exposure parameters were divided on the average value for a non-pregnant women, and presented as a box-plot to illustrate trends and variabilities.
Results
48 women (24 pregnant and 24 non-pregnant patients) completed the pharmacokinetic study (one pregnant woman was lost to follow-up due to moving out of the study area). No adverse effects, related to study treatment, were observed and treatment efficacy was excellent in both groups with total parasite clearance by day three 22 . Consort checklist and flow-chart are available from figshare 29 ). Parasites were detected in one pregnant woman at a revisit at day 49, classified as a new infection by genotyping. No recrudescent malaria was observed in any of the patients.
Demographic and clinical data are presented in Table 1 . In both groups age, weight and height were comparable, but a higher parasite density and a significantly lower haemoglobin level were found in the pregnant women. The frequent sampling design resulted in full pharmacokinetic concentration-time profiles for artesunate and dihydroartemisinin in both groups. Artesunate was rapidly converted into dihydroartemisinin, and artesunate concentrations reached the LLOQ within six hours in all patients. 62% of the artesunate samples, and 21% of the dihydroartemisinin samples were measured to be below the LLOQ.
Pharmacokinetic analysis
The pharmacokinetic properties of artesunate and dihydroartemisinin were described simultaneously in a drug-metabolite model, assuming complete in vivo conversion of artesunate into dihydroartemisinin ( Figure 1) . A transit-compartment (n = 3) absorption model for artesunate was superior to all other absorption models tested (ΔOFV > 242). Allowing for inter-individual variability in the relative bioavailability of artesunate improved the model fit substantially (ΔOFV = 27). Artesunate disposition was defined by a central disposition compartment with no additional benefit of adding a peripheral disposition compartment (p > 0.05). Dihydroartemisinin was best described by a onecompartment disposition model with first-order elimination. However, an additional peripheral disposition compartment for dihydroartemisinin improved the model fit significantly (ΔOFV = 21), but resulted in an unrealistic terminal elimination half-life of 9 hours and was therefore not carried forward [30] [31] [32] [33] . A third disposition compartment did not improve the model fit (p > 0.05). Ignoring data below the LLOQ (missing data) or imputing them as half the LLOQ resulted in model misspecifications due to the large fraction of censored data (results not shown). The best performing model was obtained when data below the LLOQ was modelled as categorical data (i.e. M3), thereby maximizing the probability that observations below the LLOQ are predicted to be below the LLOQ (Figure 2 ). Inter-individual variability was retained on artesunate elimination clearance, dihydroartemisinin elimination clearance, mean-transit-time, and relative bioavailability. A separate additive error model for artesunate and dihydroartemisinin, respectively, described the random residual variability adequately.
Body weight implemented as an allometric function on clearance and volume parameters, improved the model fit (ΔOFV = 6.3) and was retained in the final model due to the strong biological prior of this covariate, and to remove the potential bias of systematically different body weights between pregnant and nonpregnant women. Pregnancy as a categorical covariate had a significant (ΔOFV = 20) impact on oral clearance of dihydroartemisinin, resulting in a 21% increased elimination clearance of dihydroartemisinin in pregnant women as compared to nonpregnant women. In addition, parasite biomass (ΔOFV = 10) and ALT (ΔOFV = 14) at enrolment were found to be significant covariates on the relative bioavailability; 14% increase in relative bioavailability per each increase in the natural logarithm of the parasite biomass, and 2.2% increase in relative bioavailability per each unit (IU) increase in ALT).
Final parameter estimates are summarized in Table 2 . The full covariate approach investigating the impact of pregnancy confirmed the above covariate relationship, resulting in an increased dihydroartemisinin elimination clearance of 24% in pregnant women, causing a proportional decrease in total drug exposure to dihydroartemisinin (Figure 3 ).
The final model showed satisfactory goodness-of-fit diagnostics for both artesunate and dihydroartemisinin (Figure 4 and Figure 5 ) and predictive performance (Figure 2) . The pharmacometric model code is available in Table 3 . Calculated epsilon-shrinkage was low (11.1% and 10.4% for artesunate and dihydroartemisinin, respectively) indicating that model diagnostics can be assessed reliably. However, the estimated eta shrinkage was relatively high for clearance parameters (i.e. artesunate clearance = 30%, dihydroartemisinin clearance = 40%, mean transit time = 5.7%, bioavailability = 25%) and empirical Bayes estimates should therefore be interpreted with caution
28
. Simulations of the exposure to artesunate and dihydroartemisinin in pregnant and non-pregnant women can be seen in Figure 6 .
Discussion
In this study, a population pharmacokinetic model was developed for artesunate and dihydroartemisinin in pregnant and non-pregnant women in Burkina Faso, treated with a fixed-dose combination of artesunate and mefloquine. The final model was a one-compartment disposition model for both artesunate and its active metabolite, dihydroartemisinin. Artesunate absorption was described with a flexible transit compartment model allowing for inter-individual variability in the relative bioavailability. Pregnancy had a significant impact on the elimination clearance of dihydroartemisinin, resulting in a 21% reduced drug exposure compared to non-pregnant women.
Artesunate and dihydroartemisinin population pharmacokinetics have been described previously with one-compartment disposition models in pregnant and non-pregnant women after oral administration, supporting the present findings 12, 31 . Artesunate absorption is known to be rapid and was best described by a transit compartment model (three transit compartments), which is in agreement with a previously published population pharmacokinetic model in pregnant women by Kloprogge et al. 
31
, where oral dihydroartemisinin was administered alone, pregnancy was found to influence the bioavailability of dihydroartemisinin resulting in a 38% reduction in the exposure in pregnant compared to non-pregnant women. The present analysis also identified parasite biomass as a covariate on the relative bioavailability, resulting in an increased exposure to artesunate and dihydroartemisinin in patients with higher initial parasitaemia. This covariate effect has been identified also in another study 14 . This previously published clinical study showed opposite pharmacokinetic effects of malaria (87% increase) and pregnancy (23% decrease) on the absolute oral bioavailability of artesunate 13, 14 . A sequential intravenous and oral dosing regimen in pregnant and post-partum women during the acute malaria phase and at recovery (i.e. healthy) enabled these covariate effects to be dissected and quantified. The results in the present study support these findings. In addition to the disease effect, liver enzyme levels (ALT) was found to affect the relative bioavailability, resulting in an increased exposure with increasing ALT levels. This is likely to be explained by a decreased first-pass metabolism of artesunate.
The full covariate approach supported the step-wise covariate results, demonstrating a mean increased dihydroartemisinin clearance of 24% in pregnant women compared to nonpregnant women. There was also a trend towards a decreased mean transit absorption time in pregnant women. This suggests that an additional pregnancy effect in the absorption phase might be significant in a larger patient study. There was also a trend of decreasing artesunate clearance in pregnant women but it could not be substantiated by the step-wise covariate results.
The non-compartmental analysis of this clinical study by Valea et al., demonstrated an increased exposure to artesunate in pregnant women, resulting from an unexplained decrease in artesunate elimination clearance 22 . This decrease was considered highly contradictive since elimination generally increases during pregnancy due to induced enzyme systems 34 . The increased artesunate exposure could not be explained by a model-independent analysis. Also, no significant differences were found in the ; Dihydroartemisinin COMP = (4)
; Transit compartment 1 COMP = (5) ; Transit compartment 2 COMP = (6) ; Transit compartment 3 exposure to dihydroartemisinin in the model-independent analysis, but large variability was noted and thus limited power to detect differences. In the present paper, a model based approach was implemented for a more mechanistic understanding of the impact of pregnancy on the pharmacokinetics of artesunate and dihydroartemisinin. In contradiction to the NCA analysis, no pregnancy related effect was found on clearance for artesunate although a trend towards a decreased clearance was seen in the full covariate model.
$PK ;--------------------------------Pregnancy covariate----------------------------------------------------------------------------PREGNANCY = (1 + THETA(7) * PREG) ; Linear covariate relationship for pregnancy ;----------------------------------------------------------------------------------------------------------------------------------------;------------------------------Liver enzyme level covariate--------------------------------------------------------------------LIVER = (1 + THETA(8) * (ALT -20.75)) ; Linear covariate relationship for liver enzyme ;----------------------------------------------------------------------------------------------------------------------------------------;------------------------------Parasite biomass covariate----------------------------------------------------------------------PARASITE = (1 + THETA(9) * (LNPC -5.88)) ; Linear covariate relationship for parasite biomass ;---------------------------------------------------------------------------------------------------------------------------------------
;-------------------------------M3-method for incorporating concentratoins below LLOQ----------------------------DUM = (LLOQ-IPRED) / W CUMD = PHI(DUM) ;---------------------------------------------------------------------------------------------------------------------------------------; -----------------------------------------Prediction DV>=LLOQ-------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------;---------------------------------------------Likelihood DV<LLOQ-----------------------------------------------------------IF(BQL.EQ.1) THEN ; Calculating Y for data below LLOQ F_FLAG = 1 Y = CUMD + 0.000001 ENDIF ;------------------------------------------------------------------------------------------------------------------------------------
It is well known that haemoglobin levels are decreased in pregnant women due to the increased need of iron for the mother and the foetus 35 . Indeed, haemoglobin levels were significantly lower in the pregnant group in this study. However, haemoglobin was not a significant covariate in the present study when pregnant and non-pregnant women were modelled simultaneously and separately.
In conclusion, a population pharmacokinetic model was developed for artesunate and dihydroartemisinin. A pregnancy related increase in the elimination of dihydroartemisinin was found, resulting in a proportionally decreased exposure to dihydroartemisinin. This could result in an increased risk of failure and possibly a need of increased dosing of artesunate during pregnancy; especially in low-transmission settings where the acquired immunity is relatively lower. However, the clinical relevance of a lower exposure needs to be further evaluated in prospective studies.
Data availability
Underlying data Due to ethical and security considerations, the data that supports the findings in this study can be accessed only through the Data Access Committee at Mahidol Oxford Tropical Medicine Research Unit (MORU). The application form and data sharing policy can be found here: http://www.tropmedres.ac/ data-sharing.
The full NONMEM model code describing the final population pharmacokinetic model is available in Table 3, 
Consent
The study was approved by the National Health Ethics Committee in Burkina Faso (014-2008/CE-CM). The study was registered at www.clinicaltrials.gov (NCT00701961). Study procedures and objectives were explained in the local language by the study physician before obtaining a signed informed consent.
and effect kinetics of orally administered artesunate in healthy volunteers
to increased dihydroartemisinin clearance. This is a particularly relevant contribution, as pregnant women are especially vulnerable to malaria and its consequences. In particular, we appreciate the author's clear description and thorough approach to the modeling methods.
We suggest a few clarifications.
Major Comments:
Use of allometric scaling results in weight-based dosing recommendations for patients, which can complicate dosing regimens, and at the extreme could lead to lower drug coverage in low weight women and potential toxicity for larger women. We note a relatively small change in objective function value with addition of allometric scaling to the model. Was there a detectable negative correlation between weight and drug concentration in the observed data to suggest lower concentrations in women with greater weights? It is interesting that pregnant women had higher parasite biomass, and that pregnancy and parasite biomass had opposing covariate effects on CL/F. Specifically, higher dihydroartemisinin clearance was associated with pregnancy and higher relative bioavailability associated with higher parasite biomass. Can the authors comment on how they distinguished the covariate effects of pregnancy and parasite biomass during modeling (e.g. through evaluation of residual errors, OFV, VPCs, etc)? How did including parasite biomass impact the pregnancy covariate relationship? Minor Comments:
Showing the VPC for dihydroartemisinin stratified by pregnancy status may be helpful for the reader.
Can the authors clarify which model was used for the final parameters listed in Table 2 ? One option would be to reverse the sentences in the third paragraph on page 7 of the results section as follows: "Final parameter estimates are summarized in Table 2 . The full covariate approach investigating the impact of pregnancy confirmed the above covariate relationship, resulting in an increased dihydroartemisinin elimination clearance of 24% in pregnant women, causing a proportional decrease in total drug exposure to dihydroartemisinin (Figure 3 )." Please include the change in OFV associated with adding the covariate parasite biomass in the text.
Please reword the first sentence of the results section to improve clarity. As it reads now it could be thought you had 48 pregnant women not 48 women total. Please remove the extra ")" at the end of this sentence. "In addition, parasite biomass and ALT at enrolment were found to be significant covariates on the relative bioavailability; 14% increase in relative bioavailability per each increase in the natural logarithm of the parasite biomass, and 2.2% increase in relative bioavailability per each increase in ALT)."
In summary, we thank the authors for contributing to our understanding of artesunate and dihydroartemisinin pharmacokinetics during pregnancy. We appreciate their inclusion of NONMEM code to aid understanding and future efforts investigating this combination. We agree with their conclusions that more work is needed clarify how differences in pharmacokinetics impact treatment outcomes for pregnant women with malaria who are treated with ACTs, particularly when immunity in the population is low.
Is the work clearly and accurately presented and does it cite the current literature? Yes
Is the study design appropriate and is the work technically sound? Yes 2. Can the authors clarify which model was used for the final parameters listed in Table 2 ? One option would be to reverse the sentences in the third paragraph on page 7 of the results section as follows: "Final parameter estimates are summarized in Table 2 . The full covariate approach investigating the impact of pregnancy confirmed the above covariate relationship, resulting in an increased dihydroartemisinin elimination clearance of 24% in pregnant women, causing a proportional decrease in total drug exposure to dihydroartemisinin (Figure 3 )."
Reply: Thank you for this suggestion. Changed accordingly.
3. Please include the change in OFV associated with adding the covariate parasite biomass in the text.
4. Please reword the first sentence of the results section to improve clarity. As it reads now it could be thought you had 48 pregnant women not 48 women total.
Reply: The sentence has been revised for clarity and now reads. "48 women (24 pregnant and 24 non-pregnant patients) completed the pharmacokinetic study (one pregnant woman was lost to follow-up due to moving out of the study area)."
5. Please remove the extra ")" at the end of this sentence. "In addition, parasite biomass and ALT at enrolment were found to be significant covariates on the relative bioavailability; 14% increase in relative bioavailability per each increase in the natural logarithm of the parasite biomass, and 2.2% 4.
5.
To confirm a disease effect with regard to liver status (ALT) as referred on page 9 in the first paragraph; it would seem to require data from individuals with liver disease. 4. To confirm a disease effect with regard to liver status (ALT) as referred on page 9 in the first paragraph; it would seem to require data from individuals with liver disease. It is not clear that evidence of liver disease is present in the study population. The values reported for ALT appear only slightly elevated for some individuals (perhaps isolated and transient values). AST and bilirubin values appear normal and there is no clinical description of liver disease. Please clarify the discussion with respect to the relationship between ALT and liver disease. 
Reply
